5 Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU et al. Altered microenvironmental
regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell …

Antibody-based immunotherapy represents a promising strategy to target and eliminate
chemoresistant leukemic cells. Here, we evaluated the CD33/CD3-bispecific T cell engaging …

Background: Current treatment options for R/R AML are highly inadequate. CD33 is
expressed in> 99% of AML cases. BiTE® s have been effective in R/R Acute Lymphoblastic …

CD33 is expressed in 90% of patients with acute myeloid leukemia (AML), and its
extracellular portion consists of a V domain and a C2 domain. A recent study showed that a …

AML is a cancer of the myeloid lineage that is characterized by the accumulation of
abnormal white blood cells in the bone marrow and blood. Existing therapies do not lead to …

The CD33-targeting bispecific T-cell engager (BiTE) AMG 330 proved to be highly efficient in
mediating cytolysis of acute myeloid leukemia (AML) cells in vitro and in mouse models. Yet …

Antigen-escape relapse has emerged as a major challenge for long-term disease control
after CD19-directed therapies, to which dual-targeting of CD19 and CD22 has been …

Tyrosine kinase inhibitors (TKIs) are highly effective for the treatment of chronic myeloid
leukemia (CML), but very few patients are cured. The major drawbacks regarding TKIs are …

Background: AMV564 is a novel bivalent, bispecific (2: 2) CD33/CD3 T-cell engager that
binds CD33 on target cells and CD3 on T-cells leading to T-cell-directed lysis of CD33+ …

Acute myeloid leukemia (AML) is the most common acute leukemia amongst adults with a 5-
year overall survival lower than 30%. Emerging evidence suggest that immune alterations …